I think Hunter has highlighted the main observation. Year end or...

I think Hunter has highlighted the main observation. Year end or AGM run up has historical been good.

This year may be more exciting than others with potential first patient dosed + New molecule. Also when things are going good we have had some exceptional runs and not once off.

Trend has been a great return in the long run, shorter term it’s all relative to entry point. Hopefully come to the end of patchy period and start to print greeens more consistently.

Past performance isn’t an indicator of future performance, DYOR.